Document:

SALES
AND MARKETING AGREEMENT

 

This
Sales and Marketing Agreement (the “Agreement”) is entered into August 10, 2018 (“Effective Date”)
by and between Endonovo Therapeutics, Inc. (OTCQB: ENDV), a Delaware corporation having its principal business address of 6320
Canoga Avenue, 15th Floor, Woodland Hills, CA 91367 (“ENDONOVO”) and MAGNIANT, LLC, a California
limited liability company with offices at 7343 Bolero St Carlsbad CA 92009 (“MAGNIANT”). Each of MAGNIANT and
ENDONOVO shall sometimes be referred to as a “Party” and collectively, as the “Parties”.
This Agreement supersedes and replaces in their entirety, without prejudice, any and all other agreements or contracts between
the parties, excluding the Non-Disclosure Agreement signed by the Parties.

 

WHEREAS

 

ENDONOVO
is a commercial-stage developer of non-invasive medical devices and electrotherapies marketed in the United States under the trade
names SofPulse, and Ivivi Roma.

 

ENDONOVO
desires to retain MAGNIANT to provide sales and marketing services to ENDONOVO and grant MAGNIANT exclusive rights to market and
sell the ENDONOVO products (“Products”) listed on EXHIBIT A within the territory defined in EXHIBIT B (“Territory”
which may increase or decrease during the term of the Agreement based upon the terms of this Agreement or a future agreement between
the Parties).

 

MAGNIANT
is in the business of providing sales and marketing services in the healthcare industry.

 

MAGNIANT
desires to obtain said exclusive rights to market and sell the Products in the healthcare industry, as further defined in this
Agreement.

 

Accordingly,
for good and valuable consideration, the Parties agree as follows:

 

	 	A.	DESCRIPTION
    OF SERVICES
	 	 	 
	 	1.	MAGNIANT
    will represent ENDONOVO and market and sell the Products in the given Territory and which exclusive territories are defined
    herein and excludes all rights under a separate agreement with Plagens Medical Supply Consultants, Inc. a copy of which has
    been shown to MAGNIANT) and will provide the following services:

 

	 	a)	MAGNIANT
    will be responsible for marketing and promoting the Products.
	 	b)	Any
    publication and/or distribution of printed material in the promotion of the Products shall first be approved by ENDONOVO.
    The ENDONOVO name and logo, promotional materials, and information may be used with the approval of ENDONOVO during the term
    of this agreement.
	 	c)	MAGNIANT
    will collect and convey to ENDONOVO complete contact information on each prospective customer.
	 	d)	MAGNIANT
    will be financially responsible for all marketing, selling, administrative and other expenses relating to its marketing efforts.
	 	e)	MAGNIANT
    will be responsible for sales persons and any compensation it agrees to pay for their efforts in representing ENDONOVO Products.

 

    	 

    	 

    

 

	 	2.	ENDONOVO
    and MAGNIANT will set up a mutually agreed upon infrastructure for ENDONOVO to provide the following services:

 

	 	a)	ENDONOVO
    will provide product training and ongoing support through an online resource to be developed by the parties.
	 	b)	ENDONOVO
    will provide clinical information and technical support as it is developed.
	 	c)	ENDONOVO
    will provide samples to help promote and market the Products as mutually agreed to.
	 	d)	ENDONOVO
    is responsible for manufacturing and shipping the Products.
	 	e)	ENDONOVO
    will provide to MAGNIANT written notice of all existing and new product registrations in both the United States and foreign
    countries regarding Products within ten (10) days of the execution of this Agreement or the receipt of new product registrations.
	 	f)	ENDONOVO
    will share with and distribute to MAGNIANT appropriate data regarding the Product including but not limited to research results,
    clinical and laboratory projects, published research articles or papers, and Subject Product licenses or registrations with
    government agencies.

 

	 	B.	MARKET
    AND GEOGRAPHY
	 	 	 
	 	1.	MAGNIANT
    is granted exclusivity in Healthcare markets defined in EXHIBIT B and may be modified as mutually agreed upon during the term
    of the Agreement.
	 	2.	ENDONOVO
    will identify and pursue prospective and existing customers and territories to which MAGNIANT will not have access and which
    will not generate commission due to MAGNIANT. In addition, MAGNIANT shall be non-exclusive in all activities inside or outside
    the United States not defined in Exhibit B, provided, however, that if ENDONOVO shall grant an exclusive license to any party
    for any territory or use not exclusive to MAGNIANT, MAGNIANT’s non-exclusive rights shall cease to the extent not allowed
    by such exclusive license.

 

	 	C.	COMMISSIONS

 

	 	1.	ENDONOVO
    agrees to pay MAGNIANT a commission of 25% of Gross Revenue, as defined below, if:

 

	 	a.	the
    revenue can be verified as a direct or indirect referral from MAGNIANT. Total commission for MAGNIANT and referral fees paid
    by ENDONOVO cannot exceed 25% of the purchase price.
	 	b.	MAGNIANT
    has not already received a referral fee or commission in connection with the sale. ENDONOVO will not sell in the exclusive
    Territory or establish any referral source entitled to commission in exclusive Territory without MAGNIANT’s approval
    or in accordance with the provisions set forth herein.

 

	 	2.	Gross
    revenue is defined as total revenue collected by ENDONOVO from a customer for sale by ENDONOVO to the customer any Product
    less promotional discounts, rebates, other incentive discounts and credited returns.
	 	3.	ENDONOVO
    shall pay commissions due to MAGNIANT on a monthly basis based on Gross Revenues within 20 days of the end of each calendar
    month for all billings generated by MAGNIANT. Chargebacks for uncollected billings will be reconciled and deducted from MAGNIANT’s
    commission once ENDONOVO determines the billing is unrecoverable and will need to be written off.
	 	4.	ENDONOVO
    will pay MAGNIANT a consulting fee at mutually agreed upon rates for any pre-approved direct support of existing Endonovo
    business and any other business upon which MAGNIANT is not paid a commission. The agreed upon rate must be predetermined prior
    to commencing any services.
	 	5.	Should
    ENDONOVO fail to make any payment whatsoever due and payable to the MAGNIANT hereunder at the time it is due, it shall be
    deemed an Event of Default as defined hereunder, provided however, that if ENDONOVO has reasonable grounds to dispute a payment,
    it shall not be grounds for default for the disputed portion to be withheld while the Parties seek to resolve the issue.

 

    	 

    	 

    

 

	 	6.	All
    payments due hereunder shall be paid by check or bank wire payable in United States of America currency to MAGNIANT, or to
    the account of MAGNIANT at such bank as MAGNIANT may designate by notice to ENDONOVO. Payments that are more than 10 calendar
    days late will begin to accrue interest at 1.5% per month and acceptance of such payment by MAGNIANT shall constitute an irrevocable
    waiver of any Event of Default related thereto.
	 	7.	MAGNIANT
    shall be solely responsible for all payments due to any individual or organization which may perform work on behalf of MAGNIANT
    or with whom MAGNIANT arranges to share commissions. ENDONOVO shall have no direct or implied relationship with any individual
    or entity associated with MAGNIANT, or any responsibility to provide service to these independent entities.

 

	 	D.	PRICING
	 	 	 
	 	1.	ENDONOVO
    will set the floor minimum sales price by market consistent with ENDONOVO’s overall pricing strategy internally and
    externally with third party partners.
	 	2.	ENDONOVO
    will provide volume-based pricing consistent with ENDONOVO’s overall pricing strategy internally and externally with
    third party partners

 

	 	E.	INITIAL
    TERM
	 	 	 
	 	Unless
    earlier terminated as hereinafter provided, this Agreement shall continue in full force and effect for a period of three (3)
    years from the effective date subject to the extension of term as provided in paragraph F.
	 	 	 
	 	F.	EXTENSION
    OF TERM
	 	 	 
	 	If
    MAGNIANT has met the terms of this Agreement and the threshold amounts as outlined in Exhibit B for the first three (3) years,
    MAGNIANT shall have the option to extend this Agreement for an additional three (3) years subject to the successful negotiation
    of the thresholds and commissions for the additional three (3) year term.

 

	 	G.	TERMINATION
	 	 	 
	 	1.	Termination
    for any reason:

 

	 	a.	This
    agreement may be terminated by either party for any reason with 30 days written notice.
	 	b.	If
    agreement is terminated for any reason other than Event of Default (as defined below) or non-performance (as specified below),
    commission will continue to be paid by ENDONOVO to MAGNIANT for a period of 3 years for accounts they have successfully consummated
    transactions as long as they continue to satisfactorily service said accounts.
	 	c.	Any
    and all accounts that are either the subject of a purchase order or a committed contract or where MAGNIANT can show documentation
    that leads to a reasonable likelihood of a purchase order or accepted contract and a written purchase order is received or
    a contract is signed within 90 days of the termination will be included in any survival compensation follow on rights. Upon
    any termination and as a condition to these rights, MAGNIANT shall, upon termination, provide ENDONOVO with a list of all
    potential customers covered by this provision.
	 	d.	As
    long as MAGNIANT is receiving commissions or other payments hereunder it shall, in addition to any other requirements specifically
    set forth herein, be fully subject to all of its obligations hereunder.

 

    	 

    	 

    

 

	 	2.	Termination
    in the Event of Default (as defined below):

 

	 	a.	In
    the Event of Default, either Party may terminate this Agreement by providing 30 days’ notice to the defaulting Party
    that it has elected to terminate this Agreement. The notice shall specify the nature of the default and the other party shall
    have the right to cure during such 30-day period.
	 	b.	Each
    of the following circumstances shall constitute an “Event of Default” for purposes of this Agreement:

 

	 	i.	a
    Party or its affiliate has taken an act that is intended to have, or is undertaken with willful disregard and has, the effect
    of injuring the reputation or business of the other Party in any material respect;
	 	ii.	a
    Party or its affiliate has made a willful intentional violation or after written notice, continued violation (even if inadvertent)
    of any material provision of this Agreement;
	 	iii.	the
    commission by a Party or its affiliate of an act of fraud or embezzlement;
	 	iv.	a
    Party’s commission of an intentional act or intentional failure to act (but excluding matters of business judgment)
    which harms or there is a reasonable probability will harm the other Party and/or its Affiliates;
	 	v.	a
    Party’s continual failure to perform substantially the material duties of a Party’s following 30 days written
    notice to the person of such failure, which notice shall identify the actions required to cure such failure, to the extent
    curable;
	 	vi.	a
    Party’s second failure to perform substantially the material duties of such person’s duties within twelve months
    following the cure of an earlier failure as provided in clause (v)

 

	 	c.	If
    agreement is terminated for Event of Default, commission will continue to be paid by ENDONOVO to MAGNIANT for a period of
    1 month following the notice of default.
	 	d.	In
    the event of a material breach by a Party, the other Party shall be entitled to pursue any and all remedies available at law
    or in equity

 

	 	3.	Termination
    for non-performance:

 

	 	a.	The
    exclusivity outlined in this Agreement may be terminated by ENDONOVO if at any time during the term of this Agreement the
    Performance Thresholds, included herein in Exhibit B or mutually modified by the Parties are not met by MAGNIANT.

 

	 	1.	In
    the event that the Performance Threshold is not met, MAGNIANT may protect the exclusivity of the right granted hereunder by
    paying all additional amounts due for that year ending on the last day of that year, so that the threshold is met.
	 	2.	Each
    Market or Channel is independent with respect to exclusivity and exclusivity may be terminated in one or more channels but
    will be in force in any market or channel where performance thresholds are met.
	 	3.	If
    exclusivity in one or more markets or channels is terminated, Magniant will continue to have the rights to sell on a non-exclusive
    basis and all terms and conditions will remain in force and affect.

 

	 	b.	If
    contract exclusivity is terminated for non-performance, commissions will continue to be paid on future purchases by customers
    with whom MAGNIANT had sales prior to the termination or has initiated a committed contract and continue to service satisfactorily.
	 	c.	After
    the initial 3-year performance goals are accomplished annually the Parties will establish mutually agreed revenue objectives
    for the purposes of maintaining specific exclusivity.

 

    	 

    	 

    

 

	 	4.	In
    the event that ENDONOVO terminates this agreement in connection with granting a distribution right or a licensing agreement
    on a nationwide basis for any of the markets in the Territory (“Third Party Transaction”), then for the three
    years following such termination, Magniant will be paid cash compensation as defined herein or equity-based compensation for
    all future revenues derived from MAGNIANT’s customers inclusive of customers under G. 1. (c.) in that Territory based
    on the terms of the Third Party Transaction. The compensation to MAGNIANT on sale shall be the last quarter’s compensation
    earned by MAGNIANT times twelve and shall be apportioned between cash and equity as the compensation in the transaction is
    apportioned in the payments to ENDONOVO.

 

	 	H.	OWNERSHIP/INTELLECTUAL
    PROPERTY

 

1.
Confidentiality of Proprietary Information. MAGNIANT shall keep all “Confidential Information” (as defined below),
and trade secret information of the Company confidential and shall not disseminate, disclose, publish, use for MAGNIANT’s
benefit or for another’s benefit, directly or indirectly, or permit another to use or exploit in any way any Company trade
secret or confidential information known by MAGNIANT, unless and until such information has been disseminated or made available
to the general public by the Company through no action of MAGNIANT or unless otherwise required by court order to comply with
applicable law

 

(a)
Confidential Information. As used herein the term “Confidential Information” shall refer to all Intellectual Property,
as defined below, and all data and other information (including, without limitation, proprietary information), whether or not
patentable, of the Company that is disclosed to the MAGNIANT during the term of this Agreement, which may include specifications,
know-how, trade secrets, technical and scientific information, models, business information, inventions, discoveries, practices,
methods, planned future projects, pricing, procedures, formulae, protocols, techniques, programs, website design and architecture,
schematics, software documentation, financial information, sales, business and marketing plans, contracts, and unpublished patent
applications, whether disclosed in oral, written, graphic, or electronic form. As used herein, “Confidential Information”
shall include the Confidential Information of the Company, each of its portfolio companies, and the potential portfolio companies
with which the Company is, or has been, negotiating. However, intellectual property and Confidential Information derived by MAGNIANT’s
efforts and resources shall not constitute Confidential Information for purposes of this Agreement.

 

(b)
Intellectual Property. As used herein, the term “Intellectual Property” shall refer to any and all copyrights, patents,
patent applications, patent registrations, provisional patents, business processes, data rights, moral rights, mask works, trademarks,
trade names, service marks, service names, trade dress, software, source code, trade secrets, formulations, know-how, other proprietary
rights, other Confidential Information, and any other similar rights arising out of, or enforceable under, the laws of the United
States of America or elsewhere in the world.

 

    	 

    	 

    

 

2.
All content and improvements to ENDONOVO including its marketing materials, marketing plans and its intellectual property are
the sole property of ENDONOVO. This shall apply with respect to ENDONOVO’s copyrightable works, ideas, discoveries, inventions,
applications for patents, and patents, any improvements, further inventions or improvements, and any new items discovered or developed
by ENDONOVO during the term of this Agreement. MAGNIANT shall sign all documents necessary to perfect the rights of ENDONOVO in
such intellectual property, but will not be liable for any costs associated with perfecting the rights of ENDONOVO in said property.

 

	 	I.	STOCK
    OPTIONS
	 	 	 
	 	1.	It
    is the intent of both parties that MAGNIANT be recognized upon MAGNIANT’s contribution to the increased value of ENDONOVO
    business
	 	2.	Parties
    agree to enter into a Stock Option Agreement with agreed upon strike pricing and vesting periods within 1 month of the signing
    of this agreement
	 	3.	The
    principals and initial option grants as contemplated between the parties is outlined in Exhibit C.

 

	 	J.	EXPENSE
    REIMBURSEMENT
	 	 	 
	 	1.	MAGNIANT
    shall pay all “out-of-pocket” expenses related to its marketing efforts (see paragraph A, “Description of
    Services” above), and shall not be entitled to reimbursement from ENDONOVO.
	 	2.	MAGNIANT
    will hire, train and compensate its sales and marketing resources directly

 

	 	K.	REGULAR
    REPORTING

 

ENDONOVO
will make available to MAGNIANT, on a regular and ad hoc basis detailed sales and manufacturing reports as mutually agreed upon.

 

	 	L.	INSURANCE

 

The
Parties shall each have product liability and other general insurance coverage for their respective business activities related
to the Products in commercially reasonable amounts.

 

	 	M.	RELATIONSHIP
    OF PARTIES

 

The
Parties herby acknowledge and agree that each is an independent contractor and that neither Party shall be considered to be the
agent, representative, master or servant of the other Party for any purpose whatsoever, and that neither Party has any authority
to enter into a contract, to assume any obligation or to give warranties or representations on behalf of the other Party. Nothing
in this relationship shall be construed to create a relationship of joint venture partnership, fiduciary, or other similar relationship
between the Parties.

 

	 	N.	NON
    INTERFERENCE

 

Notwithstanding
the foregoing, each Party understands that it is entering this Agreement with pre-existing, historical business relationships
unrelated to the business ventures of the other Parties, to that end, each Party is permitted to continue its normal business
ventures with its pre-existing clientele and/or in its pre-existing market. However, MAGNIANT and its affiliates shall remain
bound not to compete with ENDONOVO by marketing the same or similar Products or services during the term of this Agreement or
for a period of five years after termination except in the case where MAGNIANT has terminated the agreement for ENDONOVO or its
officer’s conviction of fraud. Because damages at law may not be adequate for the breach of this covenant, each Party shall
be entitled to seek injunctive or other equitable relief in the event of a breach hereof. This clause shall only apply in the
Territories defined herein.

 

    	 

    	 

    

 

	 	O.	GOVERNING
    POLICIES AND PROCEDURES

 

All
ENDONOVO rules, policies, and operating procedures, which will be modified from time to time by ENDONOVO concerning customer orders
and returns, customer service, customer data, and product sales will apply to customers and prospects referred by MAGNIANT.

 

	 	P.	LEGAL
    REQUIREMENTS

 

	 	1.	MAGNIANT
    and ENDONOVO agree to obtain and maintain all permits, licenses and consents (governmental and otherwise) that are necessary
    or advisable for providing the services described in Section A above and further, in providing the services described in Section
    A above, to comply with all applicable legal requirements.
	 	2.	ENDONOVO
    represents and warrants that it will comply with the requirements of all Federal, state, and local laws, statutes, and regulations,
    and all orders, writs, injunctions and decrees, applicable to it or to its business including complying with all FDA rulings
    and requirements and any and all regulatory requirements. MAGNIANT represents and warrants that it will and take all reasonable
    steps to ensure that its Representatives will comply with the requirements of all Federal, state, and local laws, statutes,
    and regulations, and all orders, writs, injunctions and decrees, applicable to it or to its business including complying with
    all FDA rulings and requirements and any and all regulatory requirements.

 

	 	Q.	INDEMNIFICATION
	 	 	 
	 	1.	ENDONOVO
    agrees to indemnify MAGNIANT, together with the officers, directors and employees of MAGNIANT, and defend and hold them harmless
    from and against all claims, losses, causes of action, liabilities, damages and expenses (including, without limitation, reasonable
    attorneys’ fees) directly arising from, incurred as a consequence of or otherwise directly attributable to the gross
    negligence of ENDONOVO in connection with the Services being provided in this Agreement.
	 	2.	MAGNIANT
    agrees to indemnify ENDONOVO, together with the officers, Directors, and employees of ENDONOVO, and defend and hold them harmless
    from and against all claims, losses, causes of action, liabilities, damages and expenses (including, without limitation, reasonable
    attorneys’ fees) directly arising from, incurred as a consequence of or otherwise directly attributable to the gross
    negligence of MAGNIANT in connection with the Services being provided in this Agreement.

 

	 	R.	ASSlGNMENT

 

Neither
party’s obligation under this Agreement may be assigned or transferred to any other person, firm, or corporation without
the prior written consent of the other party, provided that ENDONOVO’s approval of MAGNIANT’s transfer or assignment
shall be based upon ENDONOVO’s reasonable determination, in its discretion, that MAGNIANT’s transferee or assignee
has the requisite experience, resources, and financial stability to fulfill the obligations of MAGNIANT under this Agreement,
and that the transfer will not create a conflict of interest with ENDONOVO’s corporate goals. ENDONOVO may, however, assign
this Agreement without consent of MAGNIANT in connection with a merger, consolidation, acquisition or sale of substantially all
of its assets or stock, or substantially all of the assets of its business. Regardless of assignment the terms of section C.
, commissions will endure any material change in ownership or other transaction which provides the rights to Products, and
will remain in force and effect with any and all successors. Furthermore, should ENDONOVO grant a license to an affiliated party
for the sale of the Products in the Territory covered by this agreement, such license shall include an assignment of this agreement
to such affiliated party. Upon such assignment to an affiliate party, MAGINANT would receive stock options set forth herein from
both companies whereby the options granted MAGNIANT will be divided proportionately from both companies based on the retained
percentage of revenue retained by each entity going forward.

 

    	 

    	 

    

 

	 	S.	CONFIDENTIALITY

 

	 	1.	Except
    as otherwise provided in this Agreement or with the consent of the other party hereto, each of the parties agrees that all
    information including, without limitation, the terms of this Agreement, business and financial information, customer and vendor
    lists and pricing and sales information, concerning either party, or any of their respective affiliates, provided by or on
    behalf of any of them shall remain strictly confidential and secret and shall not be utilized, directly or indirectly by the
    party receiving such information for its own business purposes or for any other purpose, except and solely to the extent that
    any such information is generally known or available to the public through a source or sources other than such party hereto
    or its affiliates. Notwithstanding the foregoing, each party is hereby authorized to deliver a copy of any such information
    (a) to any person pursuant to a subpoena issued by any court or administrative agency, (b) to its accountants, attorneys or
    other agents (including employees and investors on a need to know basis) on a confidential basis and (c) otherwise as required
    by applicable law, rule, regulation or legal process including, without limitation, the Securities Act of 1933, as amended,
    and the rules and regulations promulgated thereunder, and the Securities Exchange Act of 1934, as amended, and the rules and
    regulations promulgated thereunder.
	 	2.	The
    term “Confidential Information” shall mean all of the other Party’s information which is not generally available
    to the public, and which is related to the business of the Party, including without limitation all technical, financial (including
    tax returns, balance sheets, general ledgers, income statements, accounts payable ledgers, accounts receivables ledgers, audited
    financial statements and trial balances), manufacturing, customer, employee or market information, trade secrets, scientific
    or statistical data or other proprietary information relating thereto.
	 	3.	“Confidential
    Information” also means all information or material not generally known to the public or the industry in which any Party
    is or may become engaged which: (a) gives the Party some competitive business advantage or the opportunity of obtaining such
    advantage or the disclosure of which could be detrimental to the interest of the Party; (b) is owned by the Party or in which
    the Party has an interest; and/or (c) is either marked “confidential” or “proprietary.”
	 	4.	“Confidential
    Information” includes, without limitation, the following types of information (whether or not reduced to writing): trade
    secrets, information that constitutes a trade secret under the Uniform Trade Secrets Act, inventions, proposals, tapes, file
    data, documentation, diagrams, specifications, know-how, processes, formulas, models, flowcharts, software in various stages
    of development, source codes, research and development procedures and test results, marketing techniques and materials and
    plans, price and discount lists, pricing policies, business plans, customer and vendor identities and agreements, customer
    lists, leads and employee files.

 

    	 

    	 

    

 

	 	T.	SURVIVAL

 

The
confidentiality provisions of this Agreement shall remain in full force and effect after the termination of this Agreement for
a period of five years.

 

	 	U.	GOVERNING
    LAW

 

This
Agreement shall be construed in accordance with California law, excluding its principles of conflicts of laws. The Parties hereto
agree that in any action related to this Agreement, venue shall lie solely and exclusively in State Court located in Orange County,
California, and the Parties hereby irrevocably submit to the jurisdiction of the courts in Orange County. Each Party hereby waives
any right to a jury trial in any action concerning this Agreement. The Parties agree that this Agreement shall not be construed
against any party by reason of that Party allegedly being the drafter of this Agreement.

 

	 	V.	NOTICES

 

All
notices required and permitted under this Agreement shall be in writing and shall be delivered in person or deposited in the mail,
postage prepaid to the mailing address on page 1 of this Agreement. Such address may be changed from time to time by either party
by providing written notice to the other in the manner set forth above.

 

	 	W.	ENTIRE
    AGREEMENT

 

This
Agreement contains the entire understanding of the Parties as to its subject matter. Any and all prior or contemporaneous statements,
representations, promises, or agreements between the Parties are supplanted by and merged within this Agreement, and if they are
not written or expressly incorporated by reference herein, they are considered by the Parties not to have been made, and they
are not binding on the Parties. Each Party hereby represents to the other that it is not relying upon any statement, representation,
or promise of the other that is not contained within the four corners of this Agreement. This Agreement shall not be amended or
altered orally, but rather, only by an agreement in writing signed by an authorized representative of each of the Parties.

 

	 	X.	AMENDMENT

 

This
Agreement may be modified or amended if the amendment is made in writing and is signed by both parties.

 

	 	Y.	SEVERABILITY

 

If
any provision of this Agreement shall be held to be invalid or unenforceable for any reason, the remaining provisions shall continue
to be valid and enforceable. If a Court finds that any provision of this Agreement is invalid or unenforceable, but that by limiting
such provision it would become valid and enforceable then such provision shall be deemed to be written construed and enforced
as so limited.

 

	 	Z.	WAIVER
    OF CONTRACTUAL RIGHT

 

The
failure of either party to enforce any provision of the Agreement shall not be construed as a waiver or limitation of that party’s
right to subsequently enforce and compel strict compliance with every provision of this Agreement. No waiver by a Party shall
be valid unless in writing and signed by a representative authorized to bind the Party.

 

    	 

    	 

    

 

	 	AA.	APPLICABLE
    LAW

 

This
Agreement shall be governed by the laws of the State of California, United States of America as they are applied to contracts
executed, delivered and to be performed entirely within such state.

 

	 	BB.	LEGAL
    FEES AND COSTS

 

If
a legal action is initiated by any party to this Agreement against another, arising out of or relating to the alleged performance
or non-performance of any right or obligation established hereunder, or any dispute concerning the same, any and all fees, costs
and expenses reasonably incurred by the prevailing Party or his, her or its legal counsel in investigating, preparing for, prosecuting,
defending against, or providing evidence, producing documents or taking any other action in respect of, such action shall be the
joint and several obligation of and shall be paid or reimbursed by the non-prevailing Party.

 

	 	CC.	COUNTERPARTS

 

This
Agreement may be executed in any number of counterparts each of which, once executed and delivered, shall be deemed an original
and it shall not be necessary in making proof of the agreement to produce or account for any counterpart other than the one signed
by the Party against whom enforcement is sought. Facsimile or .pdf signatures shall be acceptable and deemed as if they were original
signatures.

 

	 	DD.	NOTICES

 

All
notices in connection with this Agreement shall be in writing and shall be given by certified, registered, or first class mail
or personally delivered to the Parties at the addresses set forth below. For purposes of this Agreement, a notice shall be deemed
effective upon personal delivery to the Party or if by mail five days after transmission.

 

	 	ENDONOVO:	Endonovo
    Therapeutics, Inc.
	 	 	c/o
    Don Calabria
	 	 	Chief
    Operating Officer
	 	 	6320
    Canoga Avenue, 15th Floor
	 	 	Woodland
    Hills, CA 91367
	 	 	 
	 	MAGNIANT:	Magniant
    LLC.
	 	 	c/o
    Rob Crousore
	 	 	Principal
	 	 	7343
    Bolero Street
	 	 	Carlsbad,
    CA 92009

 

(The
Remainder of this Page is Intentionally Blank)

 

    	 

    	 

    

 

IN
WITNESS THEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

	Endonovo
    Therapeutics, Inc.	 
	 	 
	 	 	 
	By:
    	Alan
    Collier	 
	Its:
    	CEO	 
	Dated:
    	August
    10, 2018	 
	 	 	 
	Magniant,
    LLC	 
	 	 
	 	 	 
	By:	Robert
    Crousore	 
	Its:
    	Managing
    Director	 
	Dated:
    	August
    10, 2018	 

 

    	 

    	 

    

 

EXHIBIT
A

PRODUCTS

 

SofPulse®
Torino II ElectroceuticalTM System

 

ENDONOVO
will make 50 units of available to MAGNIANT at no cost for marketing purposes.

 

Right
of first offer to sell updated, next generation SofPulse product or additional products developed or acquired by ENDONOVO that
would directly compete with SofPulse or where marketing additional products in the MAGNIANT Territory and channels would be synergistic.

 

    	 

    	 

    

 

EXHIBIT
B

 

EXCLUSIVE
TERRITORY FOR US DISTRIBUTION

 

Performance
Thresholds (“Gross Revenues”):

 

 

 

The
Parties acknowledge that these Performance Thresholds will be increased by mutual agreement as additional indications for the
Products are approved or reimbursements by third parties are approved or increased.

 

Exclusive
Territory shall mean all of the United States and its territories in the markets and channels as listed here and above and commonly
known as healthcare channels: VA, DOD, Indian Health Services, Long Term Care Institutions (SNF, LTACH, IRF, ILF), Pain Clinics
and Private Pain Practices, Wound Clinics, Visiting Wound Care Physicians and Home Care Nurses.

 

Nonexclusive
Territory shall mean inside and outside the United States for all healthcare channels for which MAGNIANT will be able to sell
Product and indications not covered in the exclusive territories herein above.

 

    	 

    	 

    

 

EXHIBIT
C

STOCK
AND INCENTIVE STOCK OPTIONS

 

	1.	STOCK
    AND INCENTIVE STOCK OPTIONS

 

(a)
ENDONOVO will grant MAGNIANT 1,000,000 options to purchase shares of restricted stock at a per share price equal to the 3-day
look back of the VWAP of ENDV stock on the day of entering into the Sales and Marketing Agreement between the parties (the “Initial
Option Grant” or “IOG”). The IOG will vest monthly over a twelve-month vesting period at the rate of 83,333
per month.

 

(b)
ENDONOVO and MAGNIANT also will enter into a milestone-based Stock Option Purchase Agreement (the “SOPA”) based on
a 3-day look back of the VWAP of ENDV stock at the date such milestone is achieved (the “Option Price”). Milestones
will be based on gross revenues generated by MAGNIANT as defined in the Sales and Marketing Agreement. The parties will agree
to a revenue milestone schedule, the first of which will be granted after $1,000,000 of gross product revenues attributed to MAGNIANT
under the Sales and Marketing Agreement.

 

	 	i.	The
    number of options awarded under the SOPA will equal 5% of gross revenues ($1,000,000 X 5% = $50,000 ÷ 3-day VWAP= number
    of Options), be fully-vested with an exercise period of two years.

 

	2.	NUMBER
    OF OPTIONS AVAILABLE

 

(a)
It is the intent of both parties that MAGNIANT be recognized for MAGNIANT’s contribution to the increased value of ENDONOVO
business by way of the SOPA.

 

(b)
The total number of options available will be calculated as follows:

 

	 	i.	The
    Parties Agree to enter into a milestone-based option grant schedule related to sales volume generated by MAGNIANT as well
    as other direct or indirect MAGNIANT contributions agreed to between the parties. A key component of the schedule will be
    the calculation in 1 (b) i above.
	 	 	 
	 	ii.	The
    maximum percentage of ownership upon exercising of the aggregate of the IOG and subsequent SOPA options granted to MAGNIANT
    will not to exceed 4.99% of the existing current issued and outstanding shares of ENDONOVO’s common stock. To the extent
    ENDONOVO issues additional shares, the limit of 4.99% will include the then current issued and outstanding shares.

 

	3.	VESTING
    SCHEDULE.

 

(a)
The IOG will not be exercisable for one year and should the Sales and Marketing Agreement be terminated in the first year only
the vested shares under the IOG will be exercisable. Milestones under the SOPA will be fully vested and exercisable at the time
such milestone is achieved. For purposes of this Agreement, “Vesting Commencement Date” shall mean the commencement
date of this agreement. Notwithstanding anything to the contrary, MAGNIANT further agrees any sales of the common stock purchased
through the above options is pursuant to Rule 144 or otherwise shall be limited in volume to 2% of the volume reported for the
day of the sale and no sales after 3:30pm EST. MAGNIANT’s broker shall acknowledge these limitations in writing and MAGNIANT
shall upon request provide reasonable documentation of its compliance.

 

    	 

    	 

    

 

(b)
The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent
permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until
the earlier of the Final Exercise Date or the termination of this option.

 

	4.	EXCERCISE
    OF OPTION.

 

(a)
Form of Exercise. Each election to exercise this option shall be accompanied by a completed Notice of Stock Option Exercise
in the form attached hereto as Exhibit A, signed by MAGNIANT, and received by ENDONOVO at its principal office, accompanied by
this agreement, and payment in full in the manner provided above. MAGNIANT may purchase less than the number of shares covered
hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares.

 

(b)
Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, the options under the SOPA
may not be exercised if the Sales and Marketing Agreement between ENDONOVO and MAGNIANT dated August 10, 2018, has been terminated
due to the default of MAGNIANT.

 

(c)
Continuous Satisfactory Performance. Except as otherwise provided in this Section 3, this option may not be exercised unless
the Performance Thresholds as mutually agreed upon from time to time between ENDONOVO and MAGNIANT in terms of the Sales and Marketing
Agreement between ENDONOVO and MAGNIANT dated August 10, 2018, are achieved, and have been at all times since the Grant Date.

 

(d)
Termination of Relationship with the Company. If the Sales and Marketing Agreement between ENDONOVO and MAGNIANT dated August,
10, 2018 terminates for any reason, then, except as provided in paragraphs (e) below, the right to exercise this option shall
terminate coterminously with the end of the commission tail defined herein. Provided that this option shall be exercisable only
to the extent that MAGNIANT was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing,
if MAGNIANT, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any Sales and Marketing
Agreement between ENDONOVO and MAGNIANT, confidentiality and nondisclosure agreement or other agreement between ENDONOVO and MAGNIANT,
the right to exercise this option shall terminate immediately upon such violation.

 

(e)
Termination for Cause. If, prior to the Final Exercise Date, the Sales and Marketing Agreement between ENDONOVO and MAGNIANT
is terminated by the ENDONOVO for Cause (as defined in the Sales and Marketing Agreement), the right to exercise this option shall
terminate immediately upon the effective date of such termination of the Sales and Marketing Agreement.

 

	5.	COMPANY
    RIGHT OF FIRST REFUSAL.

 

(a)
Notice of Proposed Transfer. If MAGNIANT proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of,
by operation of law or otherwise (collectively, “transfer”) any Shares acquired upon exercise of this option, then
MAGNIANT shall first give written notice of the proposed transfer (the “Transfer Notice”) to ENDONOVO The Transfer
Notice shall name the proposed transferee and state the number of such Shares the MAGNIANT proposes to transfer (the “Offered
Shares”), the price per share and all other material terms and conditions of the transfer.

 

    	 

    	 

    

 

(b)
Company Right to Purchase. For 15 business days following its receipt of such Transfer Notice, ENDONOVO shall have the option
to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the
ENDONOVO elects to purchase all or part of the Offered Shares, it shall give written notice of such election to MAGNIANT within
such 5-day period. Within 10 days after his or her receipt of such notice, MAGNIANT shall tender to ENDONOVO at its principal
offices the certificate or certificates representing the Offered Shares to be purchased by ENDONOVO, duly endorsed in blank by
MAGNIANT or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to ENDONOVO.
Promptly following receipt of such certificate or certificates, ENDONOVO shall deliver or mail to MAGNIANT a check in payment
of the purchase price for such Offered Shares; provided that if the terms of payment set forth in the Transfer Notice were other
than cash against delivery, ENDONOVO may pay for the Offered Shares on the same terms and conditions as were set forth in the
Transfer Notice; and provided further that any delay in making such payment shall not invalidate ENDONOVO’s exercise of
its option to purchase the Offered Shares.

 

(c)
Shares Not Purchased By ENDONOVO. If the ENDONOVO does not elect to acquire all of the Offered Shares, MAGNIANT may, within
the 30-day period following the expiration of the option granted to ENDONOVO under subsection (b) above, transfer the Offered
Shares which ENDONOVO has not elected to acquire to the proposed transferee, provided that such transfer shall not be on terms
and conditions more favorable to the transferee than those contained in the Transfer Notice.

 

(d)
Consequences of Non-Delivery. After the time at which the Offered Shares are required to be delivered to ENDONOVO for transfer
to ENDONOVO pursuant to subsection (b) above, ENDONOVO shall not pay any dividend to MAGNIANT on account of such Offered Shares
or permit MAGNIANT to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but shall,
insofar as permitted by law, treat ENDONOVO as the owner of such Offered Shares

 

	6.	STOCK
    GRANT UNDER SECTION G (4)

 

In
the event that this Agreement is terminated under Section G(4), MAGNIANT shall for three years thereafter, be granted stock on
a quarterly basis with a market value on date of grant based on a 3 day VWAP, equal to the compensation MAGNIANT would have been
entitled to on the gross sales to customers to whom MAGNIANT had previously effected sales. These stock grants shall continue
for three years after the termination under G(4) and shall be paid no later than 15 days after ENDONOVO files the 10-Q or 10—K
report for such quarter with the Securities and Exchange Commission.EX-4.1

 Exhibit 4.1 

ONCOR ELECTRIC DELIVERY COMPANY LLC 

OFFICER’S CERTIFICATE 
 9-AO-9 
 ESTABLISHING THE FORM AND CERTAIN TERMS OF THE 3.70%
SENIOR SECURED 
 NOTES DUE 2028 AND THE 4.10% SENIOR SECURED NOTES DUE 2048. 

The undersigned, Kevin R. Fease, Vice President and Treasurer of Oncor Electric Delivery Company LLC (formerly TXU Electric Delivery Company
(formerly Oncor Electric Delivery Company)) (the “Company”) (all capitalized terms used herein which are not defined herein but are defined in the Indenture referred to below, shall have the meanings specified in the Indenture),
pursuant to Board Resolutions dated July 25, 2018 and Sections 102, 201, 301, 303(d) and 707(c)(ii) of the Indenture (For Unsecured Debt Securities), dated as of August 1, 2002, between the Company and The Bank of New York Mellon
Trust Company, N.A. (as successor to The Bank of New York Mellon, formerly The Bank of New York), as Trustee (the “Trustee”), as supplemented and amended by Supplemental Indenture No. 1 dated as of May 15, 2008, between
the Company and the Trustee (as heretofore supplemented and amended, the “Indenture”), does hereby certify to the Trustee that: 
  

	1.	 The Securities of the fifteenth series to be issued under the Indenture (the “2028 Notes”)
shall be initially issued in a series designated “3.70% Senior Secured Notes due 2028”, and the Securities of the sixteenth series to be issued under the Indenture (the “2048 Notes”, and together with the 2028 Notes, the
“Notes”) shall be initially issued in a series designated “4.10% Senior Secured Notes due 2048”; the 2028 Notes shall be in substantially the form set forth in Exhibit A hereto, and the 2048 Notes shall be in substantially
the form set forth in Exhibit B hereto; 

  

	2.	 (A)    The 2028 Notes shall be initially authenticated and delivered in the aggregate
principal amount of $350,000,000 (the “Initial 2028 Notes”); provided, however, that the Company may, without the consent of the Holders of the Initial 2028 Notes, create and issue additional 2028 Notes ranking equally with, and
otherwise identical in all respects to, the Initial 2028 Notes (except for the issue price therefor, the date from which interest first accrues thereon and the first interest payment date therefor), which additional 2028 Notes shall form a single
series with the Initial 2028 Notes; 

 (B)    The 2048 Notes shall be initially authenticated and
delivered in the aggregate principal amount of $450,000,000 (the “Initial 2048 Notes”); provided, however, that the Company may, without the consent of the Holders of the Initial 2048 Notes, create and issue additional 2048 Notes
ranking equally with, and otherwise identical in all respects to, the Initial 2048 Notes (except for the issue price therefor, the date from which interest first accrues thereon and the first interest payment date therefor), which additional 2048
Notes shall form a single series with the Initial 2048 Notes; 
  

	3.	 The 2028 Notes shall mature and the principal thereof shall be due and payable together with all accrued and
unpaid interest thereon on November 15, 2028 and the 2048 Notes shall mature and the principal thereof shall be due and payable together with all accrued and unpaid interest thereon on November 15, 2048, and the Company shall not have any
right to extend the Maturity of the Notes as contemplated in Section 301(d) of the Indenture; 

  
 1 

	4.	 The Notes shall bear interest as provided in the form thereof set forth in Exhibit A and Exhibit B hereto; the
Interest Payment Dates for the Notes shall be May 15 and November 15 of each year, commencing November 15, 2018; 

  

	5.	 Each installment of interest on a Note shall be payable as provided in the applicable form thereof set forth in
Exhibit A and Exhibit B hereto; the Company shall not have any right to extend any interest payment periods for the Notes as contemplated in Section 301(e) of the Indenture; 

 

	6.	 The principal of, premium, if any, each installment of interest on and Additional Interest (as defined below),
if any, on the Notes shall be payable at, and registration of transfers and exchanges in respect of the Notes may be effected at, the office or agency of the Company in The City of New York; and notices and demands to or upon the Company in respect
of the Notes and the Indenture may be served at the office or agency of the Company in The City of New York; the corporate trust office of The Bank of New York Mellon, as agent of the Trustee, will initially be the agency of the Company for such
payment, registration and registration of transfers and exchanges and service of notices and demands, and the Company hereby appoints the Trustee as its agent for all such purposes; and the Trustee will initially be the Security Registrar and the
Paying Agent for the Notes; provided, however, that the Company reserves the right to establish or change, by one or more Officer’s Certificates, any such office or agency and such agent. 

 

	7.	 The Regular Record Date for the interest payable on any given Interest Payment Date with respect to the Notes
shall be the 15th calendar day before such Interest Payment Date; 

  

	8.	 The Notes of each series are subject to redemption as provided in the applicable form thereof set forth in
Exhibit A and Exhibit B hereto; 

  

	9.	 The Notes of each series are “Benefitted Securities” and shall have the benefit of the covenant of
the Company contained in Section 707 of the Indenture and, pursuant to Section 707(b)(i) of the Indenture, the Notes are and shall be secured equally and ratably with the Secured Debt under the Indenture and the Additional Secured Debt
pursuant to, and subject to the terms and conditions of, the Deed of Trust, Security Agreement and Fixture Filing, dated as of May 15, 2008, as amended by the First Amendment to Deed of Trust, Security Agreement and Fixture Filing, dated as of
March 2, 2009, the Second Amendment to Deed of Trust, Security Agreement and Fixture Filing, dated as of September 3, 2010 and the Third Amendment to Deed of Trust, Security Agreement and Fixture Filing, dated as of November 10, 2011
(as amended, the “Deed of Trust”), by the Company to and for the benefit of The Bank of New York Mellon Trust Company, N.A. (as successor to The Bank of New York Mellon, formerly The Bank of New York) as collateral agent and trustee
thereunder; 

  
 2 

	10.	 The Notes of each series shall be issuable in denominations of $2,000 and integral multiples of $1,000 in
excess thereof; 

  

	11.	 No service charge shall be made for the registration of transfer or exchange of the Notes; provided, however,
that the Company may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in connection with the exchange or transfer; 

 

	12.	 The Notes of each series shall be initially issued in global form registered in the name of Cede & Co.
(as nominee for The Depository Trust Company (“DTC”)); provided, that the Company reserves the right to provide for another depositary, registered as a clearing agency under the Exchange Act, to act as depositary for the global
Notes (DTC and any such successor depositary, and any successor to any thereto, the “Depositary”); beneficial interests in Notes issued in global form may not be exchanged in whole or in part for individual certificated Notes in
definitive form, and no transfer of a global Note in whole or in part may be registered in the name of any Person other than the Depositary or its nominee except that (i) if the Depositary (A) has notified the Company that it is unwilling
or unable to continue as depositary for the global Notes or (B) has ceased to be a clearing agency registered under the Exchange Act and, in either case, a successor depositary for such global Notes has not been appointed within 90 days, the
Company will execute, and the Trustee, upon receipt of a Company Order for the authentication and delivery of definitive Notes, will authenticate and deliver Notes in definitive certificated form in an aggregate principal amount equal to the
aggregate principal amount of the global Notes representing such Notes in exchange for such global Notes, such definitive Notes to be registered in the names provided by the Depositary; each global Note (i) shall represent and shall be
denominated in an amount equal to the aggregate principal amount of the outstanding Notes to be represented by such global Note, (ii) shall be registered in the name of the Depositary or its nominee, (iii) shall be delivered by the Trustee
to the Depositary, its nominee, any custodian for the Depositary or otherwise pursuant to the Depositary’s instruction and (iv) shall bear a legend restricting the transfer of such global Note to any Person other than the Depositary or its
nominee; none of the Company, the Trustee, any Paying Agent, any Security Registrar or any Authenticating Agent will have any responsibility or liability for any aspect of the records relating to, or payments made on account of, or transfers of,
beneficial ownership interests in a global Note or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests; and the Notes in global form will contain restrictions on transfer, substantially as described
in the forms set forth in Exhibit A and Exhibit B hereto; 

  

	13.	 The Notes of each series will be initially issued pursuant to Section 4(a)(2) of the Securities Act of
1933, as amended (the “Securities Act”). Each Note, whether in a global form or in a certificated form, shall bear the non-registration legend and the registration rights legend in
substantially the form set forth in such applicable form, unless otherwise agreed to by the Company, such agreement to be confirmed in writing to the Trustee. DTC or its nominee shall be the Holder of such applicable global Note for all purposes
under the Indenture and the Notes, and beneficial owners with respect to such applicable global Note shall hold their interests pursuant to applicable procedures of the Depositary. The Company, the Trustee and the Security Registrar shall be
entitled to 

  
 3 

	 	
deal with the Depositary for all purposes of the Indenture relating to such applicable global Note (including the payment of principal, premium, if any, and interest, and the giving of
instructions or directions by or to the beneficial owners of such global Note) as the sole Holder of such applicable global Note and shall have no obligations to the beneficial owners thereof. Nothing in the Indenture, the Notes or this certificate
shall be construed to require the Company to register any Notes under the Securities Act, unless otherwise expressly agreed by the Company, confirmed in writing to the Trustee, or to make any transfer of such Notes in violation of applicable law.
The Company has entered into a registration rights agreement with the initial purchasers of the Notes pursuant to which, among other things, the Notes may be exchanged for notes registered under the Securities Act (the “Exchange
Notes”). The Exchange Notes shall be in substantially the form of Exhibit A with respect to the 2028 Notes, and Exhibit B, with respect to the 2048 Notes, but, in each case, without the
non-registration legend, the registration rights legend, the Certificate of Transfer and the provisions for Additional Interest. The Trustee, at the request of the Company, shall authenticate and deliver
Exchange Notes in exchange for an equal principal amount of Notes of such series; 

  

	14.	 It is contemplated that beneficial interests in Notes of each series owned by “qualified institutional
buyers” (as defined in Rule 144A under the Securities Act) (“QIBs”) or sold to QIBs in reliance upon Rule 144A under the Securities Act will be represented by one or more separate certificates in global form registered in the
name of Cede & Co., as registered owner and as nominee for DTC; beneficial interests in Notes of each series sold to foreign purchasers pursuant to Regulation S under the Securities Act will be evidenced by one or more separate certificates
in global form (each a “Regulation S Global Certificate”) and will be registered in the name of Cede & Co., as registered owner and as nominee for DTC for the accounts of Euroclear and Clearstream Banking;

 In connection with any transfer of Notes, or of any transfer of a beneficial interest in one global Note to another
global Note, as the case may be, the Trustee, the Security Registrar and the Company shall be under no duty to inquire into, may conclusively presume the correctness of, and shall be fully protected in relying upon the certificates and other
information (in the forms attached hereto as Exhibits A and B, for use in connection with the transfer of the Notes in certificated form, or Exhibit C, for use in connection with the transfer of beneficial interests in one certificate in global form
to another certificate in global form or to a Note in certificated form, or otherwise) received from the Holders and any transferees of any Notes, or from the transferors or transferees of any beneficial interest in a global Note transferred to
another global Note, as the case may be, regarding the validity, legality and due authorization of any such transfer, the eligibility of the transferee to receive such Note or such beneficial interest, as the case may be, and any other facts and
circumstances related to such transfer; 
  

	15.	 None of the Company, the Trustee or the Security Registrar shall have any liability for any acts or omissions
of the Depositary, for any Depositary records of beneficial interests, for any transactions between the Depositary or any participant member of the Depositary and/or beneficial owners, for any transfers of beneficial interests in the Notes, or in
respect of any transfers effected by the Depositary or by any participant member of the Depositary or any beneficial owner of any interest in any Notes held through any such participant member of the Depositary; 

  
 4 

	16.	 If the Company shall make any deposit of money and/or Eligible Obligations with respect to any Notes, or any
portion of the principal amount thereof, as contemplated by Section 801 of the Indenture, the Company shall not deliver an Officer’s Certificate described in clause (z) in the first paragraph of said Section 801 unless the
Company shall also deliver to the Trustee, together with such Officer’s Certificate, either: 

(A)    an instrument wherein the Company, notwithstanding the satisfaction and discharge of its indebtedness in respect of
such Notes, shall assume the obligation (which shall be absolute and unconditional) to irrevocably deposit with the Trustee or Paying Agent such additional sums of money, if any, or additional Eligible Obligations (meeting the requirements of
Section 801), if any, or any combination thereof, at such time or times, as shall be necessary, together with the money and/or Eligible Obligations theretofore so deposited, to pay when due the principal of and premium, if any, and interest due
and to become due on such Notes or portions thereof, all in accordance with and subject to the provisions of said Section 801; provided, however, that such instrument may state that the obligation of the Company to make additional deposits as
aforesaid shall be subject to the delivery to the Company by the Trustee of a notice asserting the deficiency accompanied by an opinion of an independent public accountant of nationally recognized standing, selected by the Trustee, showing the
calculation thereof; or 
 (B)    an Opinion of Counsel to the effect that, as a result of a change in law occurring
after the date of this certificate, the Holders of such Notes, or portions of the principal amount thereof, will not recognize income, gain or loss for United States federal income tax purposes as a result of the satisfaction and discharge of the
Company’s indebtedness in respect thereof and will be subject to United States federal income tax on the same amounts, at the same times and in the same manner as if such satisfaction and discharge had not been effected. 

 

	17.	 The Eligible Obligations with respect to the Notes of each series shall be Government Obligations.

  

	18.	 The 2028 Notes shall have such other terms and provisions as are provided in the form thereof set forth in
Exhibit A hereto, and the 2048 Notes shall have such other terms and provisions as are provided in the form thereof set forth in Exhibit B hereto; 

  

	19.	 No Event of Default under the Indenture has occurred or is occurring; and to the knowledge of the undersigned,
(i) no Event of Default has occurred and is continuing and (ii) no event has occurred and is continuing which entitles the Secured Parties (as defined in the Deed of Trust) under the Deed of Trust, or any of them, to accelerate the
maturity of the indebtedness secured thereby; 

  
 5 

	20.	 Subject to Section 22 of the Deed of Trust, the aggregate principal amount of indebtedness issuable under
and secured by the Deed of Trust is unlimited, and the aggregate principal indebtedness now proposed to be issued under and secured by the Deed of Trust is $6,126,278,000, consisting of Indenture Notes Obligations (as defined in the Deed of Trust)
in the aggregate principal amount of $$6,126,278,000 (including the $800,000,000 aggregate principal amount of Notes being issued on the date hereof and after taking into account the defeasance of the $550,000,000 aggregate principal amount of the
Company’s 6.80% Senior Secured Notes due 2018); 

  

	21.	 The undersigned has read all of the covenants and conditions contained in the Indenture, and the definitions in
the Indenture relating thereto, relating to the issuance and authentication and delivery of the Notes and to the creation or existence of Secured Debt pursuant to Section 707(a) and Section 707(b) of the Indenture, and in respect of
compliance with which this certificate is made; 

  

	22.	 The statements contained in this certificate are based upon the familiarity of the undersigned with the
Indenture, the documents accompanying this certificate, and upon discussions by the undersigned with officers and employees of the Company familiar with the matters set forth herein; 

 

	23.	 In the opinion of the undersigned, he has made such examination or investigation as is necessary to enable him
to express an informed opinion as to whether or not such covenants and conditions have been complied with; and 

  

	24.	 In the opinion of the undersigned, such conditions and covenants, and all conditions precedent provided for in
the Indenture (including covenants compliance with which constitutes a condition precedent) relating to the authentication and delivery of the Notes as requested in the accompanying Company Order and to the creation or existence of Secured Debt
pursuant to Section 707(a) and Section 707(b) of the Indenture, have been complied with. 

  

  
 6 

 IN WITNESS WHEREOF, I have executed this Officer’s Certificate this 10th day of August,
2018. 
  

	
	
	/s/ Kevin R. Fease
	Name: Kevin R. Fease
	Title: Vice President and Treasurer

  
 [Signature page to
Officer’s Certificate – August 2002 Indenture] 
  

 EXHIBIT A 

[FORM OF 2028 NOTE] 

[UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO ONCOR ELECTRIC DELIVERY COMPANY LLC OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS
WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.] 

[non-registration legend] 

“THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THE HOLDER HEREOF, BY PURCHASING
THIS SECURITY, AGREES FOR THE BENEFIT OF ONCOR ELECTRIC DELIVERY COMPANY LLC (THE “COMPANY”) THAT THIS SECURITY MAY NOT BE RESOLD, PLEDGED OR OTHERWISE TRANSFERRED OTHER THAN (A) (1) TO THE COMPANY, (2) IN A TRANSACTION ENTITLED
TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT, (3) SO LONG AS THIS SECURITY IS ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE SECURITIES ACT (“RULE 144A”), TO A PERSON WHOM THE SELLER REASONABLY
BELIEVES IS A “QUALIFIED INSTITUTIONAL BUYER” WITHIN THE MEANING OF RULE 144A PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE IS GIVEN THAT THE RESALE, PLEDGE OR OTHER TRANSFER IS BEING
MADE IN RELIANCE ON RULE 144A (AS INDICATED BY THE BOX CHECKED BY THE TRANSFEROR ON THE CERTIFICATE OF TRANSFER ON THE REVERSE OF THIS SECURITY), (4) IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE
SECURITIES ACT (AS INDICATED BY THE BOX CHECKED BY THE TRANSFEROR ON THE CERTIFICATE OF TRANSFER ON THE REVERSE OF THIS SECURITY), (5) IN ACCORDANCE WITH ANOTHER APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (AND
BASED UPON AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY) OR (6) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND (B) IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED
STATES OR IN ANY OTHER APPLICABLE JURISDICTION. THE HOLDER HEREOF, BY PURCHASING THIS SECURITY, REPRESENTS AND AGREES FOR THE BENEFIT OF THE COMPANY 

  
 A-1 

 
THAT IT IS (1) A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A OR (2) A NON-U.S. PERSON OUTSIDE THE UNITED STATES WITHIN THE
MEANING OF, OR AN ACCOUNT SATISFYING THE REQUIREMENTS OF PARAGRAPH (k)(2) OF RULE 902 UNDER, REGULATION S UNDER THE SECURITIES ACT.” 

[registration rights legend] 

The Holder of this Security, by acceptance hereof, will be deemed to have agreed to be bound by the provisions of the Registration Rights
Agreement dated August 10, 2018, among the Company and the initial purchasers of this Security. 

  
 A-2 

			
	
NO.               
                             
	 	CUSIP:                    

 [144A Global Certificate:     68233J BE3] 

[Regulation S Global Certificate:   U68281 AQ4] 

[Exchange Notes:     68233J BH6] 

ONCOR ELECTRIC DELIVERY COMPANY LLC 

3.70% SENIOR SECURED NOTES DUE 2028 

ONCOR ELECTRIC DELIVERY COMPANY LLC, a limited liability company duly organized and existing under the laws of the State of Delaware (herein
referred to as the “Company”, which term includes any successor Person under the Indenture referred to below), for value received, hereby promises to pay to
                        
                                
                                
                                
                                         
                                or registered assigns, the principal sum of
                                     
   
($                                 ) Dollars on
November 15, 2028, and to pay interest on said principal sum semi-annually in arrears on May 15 and November 15 of each year commencing November 15, 2018 (each an “Interest Payment Date”) at the rate of 3.70% per annum
until the principal hereof is paid or made available for payment. Interest on the Securities of this series will accrue from and including August 10, 2018, to and excluding the first Interest Payment Date, and thereafter will accrue from and
including the last Interest Payment Date to which interest has been paid or duly provided for. No interest will accrue on the Securities with respect to the day on which the Securities mature. If the Company does not comply with certain of its
obligations under the registration rights agreement dated August 10, 2018 between the Company and the parties named therein (the “Registration Rights Agreement”), this Security shall, in accordance with Section 2(e) of the
Registration Rights Agreement, bear additional interest (“Additional Interest”) in addition to the interest otherwise provided for hereunder. For purposes of this Security, the term “interest” shall be deemed to include any such
Additional Interest. In the event that any Interest Payment Date is not a Business Day, then payment of interest payable on such date will be made on the next succeeding day which is a Business Day (and without any interest or other payment in
respect of such delay) with the same force and effect as if made on the Interest Payment Date. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person
in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the 15th calendar day before such Interest Payment Date (each a “Regular Record
Date”) immediately preceding such Interest Payment Date, except that interest payable at Maturity will be payable to the Person to whom principal shall be paid. Any such interest not so punctually paid or duly provided for will forthwith cease
to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such
Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the
requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture referred to herein. 

  
 A-3 

 Payment of the principal of (and premium, if any) and interest at Maturity on this Security
shall be made upon presentation of this Security at the office or agency of the Company maintained for that purpose in The City of New York, in the State of New York, in such coin or currency of the United States of America as at the time of payment
is legal tender for payment of public and private debts; provided, however, that, at the option of the Company, interest on this Security (other than interest payable at Maturity) may be paid by check mailed to the address of the Person entitled
thereto, as such address shall appear on the Security Register, and provided, further, that if such Person is a securities depositary, such payment may be made by such other means in lieu of check as shall be agreed upon by the Company, the Trustee
and such Person. 
 All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the
Indenture and in the Officer’s Certificate establishing the terms of the Securities of this series. 
 This Security is one of a duly
authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture (For Unsecured Debt Securities) dated as of August 1, 2002 (herein, together with any
amendments or supplements thereto, including Supplemental Indenture No. 1, dated as of May 15, 2008, called the “Indenture”, which term shall have the meaning assigned to it in such instrument), between the Company and The Bank
of New York Mellon Trust Company, N.A. (as successor to The Bank of New York Mellon, formerly The Bank of New York), as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is
hereby made to the Indenture, Board Resolutions and Officer’s Certificate creating the series designated on the face hereof, for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the
Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. The acceptance of this Security shall be deemed to constitute the consent and agreement by the Holder thereof to
all of the terms and provisions of the Indenture. This Security is one of the series designated on the face hereof. 
 This Security is
subject to redemption at the election of the Company, in whole at any time or in part from time to time, at any time prior to August 15, 2028 at a redemption price as calculated by the Company equal to the greater of: 

 

	 	•	 	 100% of the principal amount of the Notes of this series being redeemed, or 

 

	 	•	 	 the sum of the present values of the remaining scheduled payments of principal and interest (excluding the
portion of any such interest accrued to the redemption date) on the Notes of this series being redeemed that would be due if the Notes matured on August 15, 2028, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 12.5 basis points, 

plus, in each case, accrued interest on those Notes of this series to, but not including, the redemption date. 

  
 A-4 

 This Security is subject to redemption at the election of the Company, in whole at any time
or in part from time to time, at any time on or after August 15, 2028, at a redemption price equal to 100% of the principal amount of the Notes of this series being redeemed, plus accrued interest on those Notes of this series to, but not
including, the redemption date. 
 “Treasury Rate” means, with respect to any redemption date, the rate per annum equal to the
semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date. 

“Comparable Treasury Issue” means the United States Treasury security selected by the Independent Investment Banker as having a
maturity comparable to the remaining term of the Notes to be redeemed (assuming for this purpose that the Notes matured on August 15, 2028) that would be utilized, at the time of selection and in accordance with customary financial practice, in
pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes. 
 “Comparable Treasury
Price” means, with respect to any redemption date, (i) the average of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) on the third business day preceding such
redemption date, as set forth in the H. 15 Daily Update of the Federal Reserve Bank or (ii) if such release (or any successor release) is not published or does not contain prices on such business day, the Reference Treasury Dealer Quotation
actually obtained by the Trustee for such redemption date. 
 “H.15 (519)” means the weekly statistical release entitled
“H.15 (519) Selected Interest Rates”, or any successor publication, published by the Board of Governors of the Federal Reserve System. 

“H.15 Daily Update” means the daily update of H.15 (519) available through the worldwide website of the Board of Governors of the
Federal Reserve System or any successor site or publication. 
 “Independent Investment Banker” means the Reference Treasury
Dealer appointed by the Company. 
 “Reference Treasury Dealer” means a primary U.S. Government securities dealer in New York City
(a “Primary Treasury Dealer”) appointed by the Company. 
 “Reference Treasury Dealer Quotation” means, with respect to
the Reference Treasury Dealer and any redemption date, the average, as determined by the Trustee, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the
Trustee by the Reference Treasury Dealer at 5:00 p.m. on the third business day preceding such redemption date. 
 Notice of redemption
(other than at the option of the Holder) shall be given by mail to Holders of Securities, not less than 30 days prior to the date fixed for redemption, all as provided in the Indenture. As provided in the Indenture, notice of redemption at the
election of the Company as aforesaid may state that such redemption shall be conditional upon the receipt by 

  
 A-5 

 
the applicable Paying Agent or Agents of money sufficient to pay the principal of and premium, if any, and interest, if any, on this Security on or prior to the date fixed for such redemption; a
notice of redemption so conditioned shall be of no force or effect if such money is not so received and, in such event, the Company shall not be required to redeem this Security. 

In the event of redemption of this Security in part only, a new Security or Securities of this series of like tenor representing the
unredeemed portion hereof shall be issued in the name of the Holder hereof upon the cancellation hereof. 
 The Indenture contains
provisions for defeasance at any time of the entire indebtedness of this Security upon compliance with certain conditions set forth in the Indenture. 

The obligations of the Company with respect to the Notes are secured by a lien granted pursuant to the Deed of Trust, Security Agreement and
Fixture Filing, dated as of May 15, 2008, as amended, by the Company to and for the benefit of The Bank of New York Mellon Trust Company, N.A. (as successor to The Bank of New York Mellon, formerly The Bank of New York), as collateral agent and
trustee thereunder. 
 If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the
Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 
 The Indenture
permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any
time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of all series to be affected. The Indenture also contains provisions permitting the Holders of specified
percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past
defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the
registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 

As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any
proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to
the Securities of this series, the Holders of a majority in aggregate principal amount of the Securities of all series at the time Outstanding in respect of which an Event of Default shall have occurred and be continuing shall have made written
request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee reasonable indemnity, and the Trustee shall not have received from the Holders of a majority in aggregate principal amount of
Securities of all series at the time Outstanding in respect of which an Event of Default shall have occurred and be continuing a direction inconsistent with such request, and 

  
 A-6 

 
shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of
this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 

No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the
Company, which is absolute and unconditional, to pay the principal of and any premium and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed. 

The Securities of this series are issuable only in registered form without coupons in denominations of $2,000 and integral multiples of $1,000
in excess thereof. As provided in the Indenture and subject to certain limitations therein and herein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor and of
authorized denominations, as requested by the Holder surrendering the same. 
 No service charge shall be made for any such registration of
transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

The Company shall not be required to execute and the Security Registrar shall not be required to register the transfer of or exchange of
(a) Securities of this series during a period of 15 days immediately preceding the date notice is given identifying the serial numbers of the Securities of this series called for redemption or (b) any Security so selected for redemption in
whole or in part, except the unredeemed portion of any Security being redeemed in part. The Company shall not be required to make transfers or exchanges of the Securities of this series for a period of 15 days next preceding an Interest Payment
Date. 
 The Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered
as the absolute owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 

Each Holder shall be deemed to understand that the offer and sale of the Securities of this series have not been registered under the
Securities Act and that the Securities of this series may not be resold, pledged or otherwise transferred other than as permitted in the following sentence. Each Holder shall be deemed to agree, on its own behalf and on behalf of any accounts for
which it is acting as hereinafter stated, that if such Holder resells, pledges or otherwise transfers any Securities of this series, such Holder will do so only (A) to the Company, (B) in a transaction entitled to an exemption from
registration provided by Rule 144 under the Securities Act, (C) so long as Securities of this series are eligible for resale pursuant to Rule 144A under the Securities Act, to a Person whom such Holder reasonably believes is a “qualified
institutional buyer” within the meaning of Rule 144A that purchases for its own account or for the account of a qualified institutional buyer to whom notice is given that the resale, pledge or transfer is being made in reliance on Rule 144A,
(D) in an offshore transaction in accordance with Rule 903 or Rule 904 of Regulation S under the Securities Act, (E) in accordance with another applicable exemption from the registration requirements of the Securities Act (and based upon
an opinion of 

  
 A-7 

 
counsel acceptable to the Company), or (F) pursuant to an effective registration statement under the Securities Act, and each Holder is further deemed to agree to provide to any Person
purchasing any of the Securities of this series from it a notice advising such purchaser that resales of the Securities of this series are restricted as stated herein. 

Each Holder shall be deemed to understand that, on any proposed resale of any Securities of this series pursuant to the exemption from
registration under Rule 144 under the Securities Act, any Holder making any such proposed resale will be required to furnish to the Trustee and the Company such certifications, legal opinions and other information as the Trustee and the Company may
reasonably require to confirm that the proposed sale complies with the foregoing restrictions. 
 This Security shall be governed by and
construed in accordance with the laws of the State of New York (including without limitation Section 5-1401 of the New York General Obligations Law or any successor to such statute), except to the extent
that the Trust Indenture Act shall be applicable and except to the extent that the laws of the State of Texas shall mandatorily govern. 

As provided in the Indenture, no recourse shall be had for the payment of the principal of or premium, if any, or interest on any Securities,
or any part thereof, or for any claim based thereon or otherwise in respect thereof, or of the indebtedness represented thereby, or upon any obligation, covenant or agreement under the Indenture, against, and no personal liability whatsoever shall
attach to, or be incurred by, any incorporator, stockholder, member, officer or director, as such, past, present or future of the Company or of any predecessor or successor corporation (either directly or through the Company or a predecessor or
successor corporation), whether by virtue of any constitutional provision, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly agreed and understood that the Indenture and all the Securities
are solely corporate obligations and that any such personal liability is hereby expressly waived and released as a condition of, and as part of the consideration for, the execution of the Indenture and the issuance of the Securities. 

Unless the certificate of authentication hereon has been executed by the Trustee referred to herein by manual signature, this Security shall
not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 
 IN WITNESS WHEREOF, the Company has caused
this instrument to be duly executed. 
  

			
	ONCOR ELECTRIC DELIVERY COMPANY LLC
		
	By:	 	 

  
 A-8 

 [FORM OF CERTIFICATE OF AUTHENTICATION] 

CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

Dated: 
  

			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE
		
	By:	 	 
		 	Authorized Signatory

  
 A-9 

 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL NOTE 

The following increases or decreases in this Global Note have been made: 

 

																	
	Date	 	Amount of
decrease in
Principal Amount
of this Global Note	 	 	Amount of
increase in
Principal Amount
of this Global Note	 	 	Principal Amount
of this Global
Note following
such decrease
or increase	 	 	Signature of
authorized signatory
of Corporate
Trustee or
Securities Custodian	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

  
 A-10 

 EXHIBIT B 

[FORM OF 2048 NOTE] 

[UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO ONCOR ELECTRIC DELIVERY COMPANY LLC OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS
WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.] 

[non-registration legend] 

“THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THE HOLDER HEREOF, BY PURCHASING
THIS SECURITY, AGREES FOR THE BENEFIT OF ONCOR ELECTRIC DELIVERY COMPANY LLC (THE “COMPANY”) THAT THIS SECURITY MAY NOT BE RESOLD, PLEDGED OR OTHERWISE TRANSFERRED OTHER THAN (A) (1) TO THE COMPANY, (2) IN A TRANSACTION ENTITLED
TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT, (3) SO LONG AS THIS SECURITY IS ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE SECURITIES ACT (“RULE 144A”), TO A PERSON WHOM THE SELLER REASONABLY
BELIEVES IS A “QUALIFIED INSTITUTIONAL BUYER” WITHIN THE MEANING OF RULE 144A PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE IS GIVEN THAT THE RESALE, PLEDGE OR OTHER TRANSFER IS BEING
MADE IN RELIANCE ON RULE 144A (AS INDICATED BY THE BOX CHECKED BY THE TRANSFEROR ON THE CERTIFICATE OF TRANSFER ON THE REVERSE OF THIS SECURITY), (4) IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE
SECURITIES ACT (AS INDICATED BY THE BOX CHECKED BY THE TRANSFEROR ON THE CERTIFICATE OF TRANSFER ON THE REVERSE OF THIS SECURITY), (5) IN ACCORDANCE WITH ANOTHER APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (AND
BASED UPON AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY) OR (6) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND (B) IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED
STATES OR IN ANY OTHER APPLICABLE JURISDICTION. THE HOLDER HEREOF, BY PURCHASING THIS SECURITY, REPRESENTS AND AGREES FOR THE BENEFIT OF THE COMPANY 

  
 B-1 

 
THAT IT IS (1) A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A OR (2) A NON-U.S. PERSON OUTSIDE THE UNITED STATES WITHIN THE
MEANING OF, OR AN ACCOUNT SATISFYING THE REQUIREMENTS OF PARAGRAPH (k)(2) OF RULE 902 UNDER, REGULATION S UNDER THE SECURITIES ACT.” 

[registration rights legend] 

The Holder of this Security, by acceptance hereof, will be deemed to have agreed to be bound by the provisions of the Registration Rights
Agreement dated August 10, 2018, among the Company and the initial purchasers of this Security. 

  
 B-2 

			
	
NO.               
                             
	 	CUSIP:                    

 [144A Global Certificate:     68233J BF0] 

[Regulation S Global Certificate:   U68281 AR2] 

[Exchange Notes:     68233J BG8] 

ONCOR ELECTRIC DELIVERY COMPANY LLC 

4.10% SENIOR SECURED NOTES DUE 2048 

ONCOR ELECTRIC DELIVERY COMPANY LLC, a limited liability company duly organized and existing under the laws of the State of Delaware (herein
referred to as the “Company”, which term includes any successor Person under the Indenture referred to below), for value received, hereby promises to pay to
                        
                                
                                
                                
                                         
                                or registered assigns, the principal sum of
                                     
   
($                                 ) Dollars on
November 15, 2048, and to pay interest on said principal sum semi-annually in arrears on May 15 and November 15 of each year commencing November 15, 2018 (each an “Interest Payment Date”) at the rate of 4.10% per annum
until the principal hereof is paid or made available for payment. Interest on the Securities of this series will accrue from and including August 10, 2018, to and excluding the first Interest Payment Date, and thereafter will accrue from and
including the last Interest Payment Date to which interest has been paid or duly provided for. No interest will accrue on the Securities with respect to the day on which the Securities mature. If the Company does not comply with certain of its
obligations under the registration rights agreement dated August 10, 2018 between the Company and the parties named therein (the “Registration Rights Agreement”), this Security shall, in accordance with Section 2(e) of the
Registration Rights Agreement, bear additional interest (“Additional Interest”) in addition to the interest otherwise provided for hereunder. For purposes of this Security, the term “interest” shall be deemed to include any such
Additional Interest. In the event that any Interest Payment Date is not a Business Day, then payment of interest payable on such date will be made on the next succeeding day which is a Business Day (and without any interest or other payment in
respect of such delay) with the same force and effect as if made on the Interest Payment Date. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person
in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the 15th calendar day before such Interest Payment Date (each a “Regular Record
Date”) immediately preceding such Interest Payment Date, except that interest payable at Maturity will be payable to the Person to whom principal shall be paid. Any such interest not so punctually paid or duly provided for will forthwith cease
to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such
Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the
requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture referred to herein. 

  
 B-3 

 Payment of the principal of (and premium, if any) and interest at Maturity on this Security
shall be made upon presentation of this Security at the office or agency of the Company maintained for that purpose in The City of New York, in the State of New York, in such coin or currency of the United States of America as at the time of payment
is legal tender for payment of public and private debts; provided, however, that, at the option of the Company, interest on this Security (other than interest payable at Maturity) may be paid by check mailed to the address of the Person entitled
thereto, as such address shall appear on the Security Register, and provided, further, that if such Person is a securities depositary, such payment may be made by such other means in lieu of check as shall be agreed upon by the Company, the Trustee
and such Person. 
 All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the
Indenture and in the Officer’s Certificate establishing the terms of the Securities of this series. 
 This Security is one of a duly
authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture (For Unsecured Debt Securities) dated as of August 1, 2002 (herein, together with any
amendments or supplements thereto, including Supplemental Indenture No. 1, dated as of May 15, 2008, called the “Indenture”, which term shall have the meaning assigned to it in such instrument), between the Company and The Bank
of New York Mellon Trust Company, N.A. (as successor to The Bank of New York Mellon, formerly The Bank of New York), as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is
hereby made to the Indenture, Board Resolutions and Officer’s Certificate creating the series designated on the face hereof, for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the
Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. The acceptance of this Security shall be deemed to constitute the consent and agreement by the Holder thereof to
all of the terms and provisions of the Indenture. This Security is one of the series designated on the face hereof. 
 This Security is
subject to redemption at the election of the Company, in whole at any time or in part from time to time, at any time prior to May 15, 2048 at a redemption price as calculated by the Company equal to the greater of: 

 

	 	•	 	 100% of the principal amount of the Notes of this series being redeemed, or 

 

	 	•	 	 the sum of the present values of the remaining scheduled payments of principal and interest (excluding the
portion of any such interest accrued to the redemption date) on the Notes of this series being redeemed that would be due if the Notes matured on May 15, 2048, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, 

plus, in each case, accrued interest on those Notes of this series to, but not including, the redemption date. 

  
 B-4 

 This Security is subject to redemption at the election of the Company, in whole at any time
or in part from time to time, at any time on or after May 15, 2048, at a redemption price equal to 100% of the principal amount of the Notes of this series being redeemed, plus accrued interest on those Notes of this series to, but not
including, the redemption date. 
 “Treasury Rate” means, with respect to any redemption date, the rate per annum equal to the
semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date. 

“Comparable Treasury Issue” means the United States Treasury security selected by the Independent Investment Banker as having a
maturity comparable to the remaining term of the Notes to be redeemed (assuming for this purpose that the Notes matured on May 15, 2048) that would be utilized, at the time of selection and in accordance with customary financial practice, in
pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes. 
 “Comparable Treasury
Price” means, with respect to any redemption date, (i) the average of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) on the third business day preceding such
redemption date, as set forth in the H. 15 Daily Update of the Federal Reserve Bank or (ii) if such release (or any successor release) is not published or does not contain prices on such business day, the Reference Treasury Dealer
Quotation actually obtained by the Trustee for such redemption date. 
 “H.15 (519)” means the weekly statistical release entitled
“H.15 (519) Selected Interest Rates”, or any successor publication, published by the Board of Governors of the Federal Reserve System. 

“H.15 Daily Update” means the daily update of H.15 (519) available through the worldwide website of the Board of Governors of the
Federal Reserve System or any successor site or publication. 
 “Independent Investment Banker” means the Reference Treasury
Dealer appointed by the Company. 
 “Reference Treasury Dealer” means a primary U.S. Government securities dealer in New York City
(a “Primary Treasury Dealer”) appointed by the Company. 
 “Reference Treasury Dealer Quotation” means, with respect to
the Reference Treasury Dealer and any redemption date, the average, as determined by the Trustee, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the
Trustee by the Reference Treasury Dealer at 5:00 p.m. on the third business day preceding such redemption date. 
 Notice of redemption
(other than at the option of the Holder) shall be given by mail to Holders of Securities, not less than 30 days prior to the date fixed for redemption, all as provided in the Indenture. As provided in the Indenture, notice of redemption at the
election of the Company as aforesaid may state that such redemption shall be conditional upon the receipt by 

  
 B-5 

 
the applicable Paying Agent or Agents of money sufficient to pay the principal of and premium, if any, and interest, if any, on this Security on or prior to the date fixed for such redemption; a
notice of redemption so conditioned shall be of no force or effect if such money is not so received and, in such event, the Company shall not be required to redeem this Security. 

In the event of redemption of this Security in part only, a new Security or Securities of this series of like tenor representing the
unredeemed portion hereof shall be issued in the name of the Holder hereof upon the cancellation hereof. 
 The Indenture contains
provisions for defeasance at any time of the entire indebtedness of this Security upon compliance with certain conditions set forth in the Indenture. 

The obligations of the Company with respect to the Notes are secured by a lien granted pursuant to the Deed of Trust, Security Agreement and
Fixture Filing, dated as of May 15, 2008, as amended, by the Company to and for the benefit of The Bank of New York Mellon Trust Company, N.A. (as successor to The Bank of New York Mellon, formerly The Bank of New York), as collateral agent and
trustee thereunder. 
 If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the
Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 
 The Indenture
permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any
time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of all series to be affected. The Indenture also contains provisions permitting the Holders of specified
percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past
defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the
registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 

As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any
proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to
the Securities of this series, the Holders of a majority in aggregate principal amount of the Securities of all series at the time Outstanding in respect of which an Event of Default shall have occurred and be continuing shall have made written
request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee reasonable indemnity, and the Trustee shall not have received from the Holders of a majority in aggregate principal amount of
Securities of all series at the time Outstanding in respect of which an Event of Default shall have occurred and be continuing a direction inconsistent with such request, and 

  
 B-6 

 
shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of
this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 

No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the
Company, which is absolute and unconditional, to pay the principal of and any premium and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed. 

The Securities of this series are issuable only in registered form without coupons in denominations of $2,000 and integral multiples of $1,000
in excess thereof. As provided in the Indenture and subject to certain limitations therein and herein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor and of
authorized denominations, as requested by the Holder surrendering the same. 
 No service charge shall be made for any such registration of
transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

The Company shall not be required to execute and the Security Registrar shall not be required to register the transfer of or exchange of
(a) Securities of this series during a period of 15 days immediately preceding the date notice is given identifying the serial numbers of the Securities of this series called for redemption or (b) any Security so selected for redemption in
whole or in part, except the unredeemed portion of any Security being redeemed in part. The Company shall not be required to make transfers or exchanges of the Securities of this series for a period of 15 days next preceding an Interest Payment
Date. 
 The Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered
as the absolute owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 

Each Holder shall be deemed to understand that the offer and sale of the Securities of this series have not been registered under the
Securities Act and that the Securities of this series may not be resold, pledged or otherwise transferred other than as permitted in the following sentence. Each Holder shall be deemed to agree, on its own behalf and on behalf of any accounts for
which it is acting as hereinafter stated, that if such Holder resells, pledges or otherwise transfers any Securities of this series, such Holder will do so only (A) to the Company, (B) in a transaction entitled to an exemption from
registration provided by Rule 144 under the Securities Act, (C) so long as Securities of this series are eligible for resale pursuant to Rule 144A under the Securities Act, to a Person whom such Holder reasonably believes is a “qualified
institutional buyer” within the meaning of Rule 144A that purchases for its own account or for the account of a qualified institutional buyer to whom notice is given that the resale, pledge or transfer is being made in reliance on Rule 144A,
(D) in an offshore transaction in accordance with Rule 903 or Rule 904 of Regulation S under the Securities Act, (E) in accordance with another applicable exemption from the registration requirements of the Securities Act (and based upon
an opinion of 

  
 B-7 

 
counsel acceptable to the Company), or (F) pursuant to an effective registration statement under the Securities Act, and each Holder is further deemed to agree to provide to any Person
purchasing any of the Securities of this series from it a notice advising such purchaser that resales of the Securities of this series are restricted as stated herein. 

Each Holder shall be deemed to understand that, on any proposed resale of any Securities of this series pursuant to the exemption from
registration under Rule 144 under the Securities Act, any Holder making any such proposed resale will be required to furnish to the Trustee and the Company such certifications, legal opinions and other information as the Trustee and the Company may
reasonably require to confirm that the proposed sale complies with the foregoing restrictions. 
 This Security shall be governed by and
construed in accordance with the laws of the State of New York (including without limitation Section 5-1401 of the New York General Obligations Law or any successor to such statute), except to the extent
that the Trust Indenture Act shall be applicable and except to the extent that the laws of the State of Texas shall mandatorily govern. 

As provided in the Indenture, no recourse shall be had for the payment of the principal of or premium, if any, or interest on any Securities,
or any part thereof, or for any claim based thereon or otherwise in respect thereof, or of the indebtedness represented thereby, or upon any obligation, covenant or agreement under the Indenture, against, and no personal liability whatsoever shall
attach to, or be incurred by, any incorporator, stockholder, member, officer or director, as such, past, present or future of the Company or of any predecessor or successor corporation (either directly or through the Company or a predecessor or
successor corporation), whether by virtue of any constitutional provision, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly agreed and understood that the Indenture and all the Securities
are solely corporate obligations and that any such personal liability is hereby expressly waived and released as a condition of, and as part of the consideration for, the execution of the Indenture and the issuance of the Securities. 

Unless the certificate of authentication hereon has been executed by the Trustee referred to herein by manual signature, this Security shall
not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 
 IN WITNESS WHEREOF, the Company has caused
this instrument to be duly executed. 
  

			
	ONCOR ELECTRIC DELIVERY COMPANY LLC
		
	By:	 	 

  
 B-8 

 [FORM OF CERTIFICATE OF AUTHENTICATION] 

CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

Dated: 
  

			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE
		
	By:	 	 
		 	Authorized Signatory

  
 B-9 

 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL NOTE 

The following increases or decreases in this Global Note have been made: 

 

																	
	Date	 	Amount of
decrease in
Principal Amount
of this Global Note	 	 	Amount of
increase in
Principal Amount
of this Global Note	 	 	Principal Amount
of this Global
Note following
such decrease
or increase	 	 	Signature of
authorized signatory
of Corporate
Trustee or
Securities Custodian	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

  
 B-10 

 Exhibit C 

[FORM OF CERTIFICATE OF TRANSFER] 

CERTIFICATE OF TRANSFER 
 [____]%
SENIOR SECURED NOTES DUE [____] 
 FOR VALUE RECEIVED, the undersigned sells, assigns and transfers unto 

PLEASE INSERT SOCIAL SECURITY OR 
 OTHER IDENTIFYING NUMBER OF
ASSIGNEE 
 Name and address of assignee must be printed or typewritten. 

the within Security of the Company and does hereby irrevocably constitute and appoint
                                      
                               to transfer the said Security on the books of the
within-named Company, with full power of substitution in the premises. 
 The undersigned certifies that said Security is being resold, pledged or otherwise
transferred as follows: (check one) 
  

	☐	 to the Company; 

  

	☐	 to a Person whom the undersigned reasonably believes is a “qualified institutional buyer” within the
meaning of Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) purchasing for its own account or for the account of a qualified institutional buyer to whom notice is given that the resale, pledge or other transfer
is being made in reliance on Rule 144A; 

  

	☐	 in an offshore transaction in accordance with Rule 903 or Rule 904 of Regulation S under the Securities Act;

  

	☐	 as otherwise permitted by the non-registration legend appearing on this
Security; or 

  

	☐	 as otherwise agreed by the Company, confirmed in writing to the Trustee, as follows: [describe]

 Notice:     The signature to this assignment must correspond with the name as written upon the face of the within
instrument in every particular without alteration or enlargement, or any change whatsoever. 

Dated:                       
                    

Signature:                       
                    

SIGNATURE GUARANTEE 
 Signatures must be
guaranteed by an “eligible guarantor institution” meeting the requirements of the Trustee and the Security Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program
(“STAMP”) or such other “signature guarantee program” as may be determined by the Trustee and the Security Registrar in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as
amended. 

  
 C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]